< Brochure Homepage | Faculty Index | Pathology Homepage



Email baras@jhmi.edu
Phone

Alexander Baras, M.D., Ph.D.

Assistant Professor
Primary Appointment in Pathology
Secondary Appointment in Urology


The implementation of high-throughput, global analytic methodologies for various biomolecules is ushering in a new era of discovery in disease pathogenesis. Leveraging these technologies in the development of novel diagnostics and therapeutic approaches is the crux of “precision medicine”. As a pathologist and bioinformatician, I aim to develop analytics, infrastructure, and resources for the Department and our institution as a whole that will better enable the discovery of previously unidentified features of disease that can better guide patient management, whether their modality be based on tissue morphology, protein expression, RNA analysis, genomic analysis, or other. My main area of translational research focuses on urothelial carcinoma in which my research team has identified both clinical parameters and novel molecular biomarkers that can predict which patients will benefit from platinum based neoadjuvant chemotherapy for muscle invasive disease. Additionally, our group is currently studying how the interaction of the patient's immune system plays into both the prognosis and optimal therapeutic strategy for patients with urothelial carcinoma.

Publications

Baras A*, Gandhi NM*, Munari E, Faraj S, Shultz L, Marchionni L, Schoenberg MP, Hahn NM, Hoque MO, Berman D, Bivalacqua TJ, Netto GJ. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLOS ONE. 2015 June. Accepted for publication, in production.

Gandhi NM*, Baras A*, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, Bivalacqua TJ. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol. 2015 May;33(5):204.e1-7. doi: 10.1016/j.urolonc.2015.02.011. Epub 2015 Mar 23. PubMed PMID: 25814145.

Gandhi NM*, Baras A*, Munari E, Faraj S, Reis LO, Liu JJ, Kates M, Hoque MO, Berman D, Hahn NM, Eisenberger M, Netto GJ, Schoenberg MP, Bivalacqua TJ. Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol. 2015 May;33(5):204.e1-7. doi: 10.1016/j.urolonc.2015.02.011. Epub 2015 Mar 23. PubMed PMID: 25814145.

Michailidi C, Hayashi M, Datta S, Sen T, Zenner K, Oladeru O, Brait M, Izumchenko E, Baras A, VandenBussche C, Argos M, Bivalacqua TJ, Ahsan H, Hahn NM, Netto GJ, Sidransky D, Hoque MO. Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use. Cancer Prev Res (Phila). 2015 Mar;8(3):208-21. doi: 10.1158/1940-6207.CAPR-14-0251. Epub 2015 Jan 13. PubMed PMID: 25586904; PubMed Central PMCID: PMC4355280.

Smith SC*, Baras AS*, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res. 2012 Jul 15;72(14):3480-91. doi: 10.1158/0008-5472.CAN-11-3966. Epub 2012 May 14. PubMed PMID: 22586063; PubMed Central PMCID: PMC3842017.

* co-first authorship



 


Copyright © 2017 Johns Hopkins University. All Rights Reserved